Heritage Global Inc. Third Quarter 2026 Earnings Call - HERITAGE GLOBAL INC

Explicit Guidance:

• No formal numerical guidance (revenue, EPS, margins, capex) was provided for FY2026, FY2027, or future periods.
• Qualitative revenue timing: Significant revenue from the HGP joint venture's real estate monetization (lease sale/development) is anticipated to begin in 2027 and may not be completed until 2028.
• Cost outlook: Management expects wind-down operating costs for the HGC segment to be limited to 2026, aiming to wrap up the wind-down quickly to prevent trailing costs into 2027; Q4 is projected to see similar ~$250,000 costs in the specialty lending segment as Q3.
• Recovery outlook: Potential recovery data on HGC write-downs is expected to be reported in the March 2027 call.

Business-Segment Outlook:

• Industrial Assets: Strong momentum expected to continue into Q4 2026 and extend through 2027; management anticipates repeatable large-scale transactions across transportation, metalworking, semiconductor, medical device, and pharma/biotech sectors.
• Dedex (Financial Assets): Performance is currently below expectations due to a slower-than-anticipated pace in monetizing the $1 trillion commercial loan portfolio coming due; however, management forecasts a much stronger Q4 2026 and remains confident in the business's potential.
• Boston Note: Exceeding early integration and execution goals; contributing positively to the financial assets division.
• NLEX: Steady performance in the non-performing loan (NPL) and charge-off space; growth strategy focuses on increasing volume to offset slowing price increases, driven by rising alternative lending capital raises and conversion of NPLs to charge-offs.
• HGC (Heredity Global Capital): Business is being wound down; management expects to complete the exit and fully integrate the three complementary asset-light sectors by 2027 to compete effectively.
• HGP Joint Venture: Executing five auctions of over 5,000 lots of pharmaceutical and biotech assets in 2026 to monetize equipment; real estate monetization (long-term value driver) begins 2027.

Market and Competitive Outlook:

• Auction Market: Management views the market as a "trailing benefactor" to recent economic stress; notes a lag effect where previous layoffs and Chapter 11 filings (2024–2025) are converting to Chapter 7s and asset liquidations now, benefiting auction volume in late 2026 and 2027.
• Pricing Dynamics: NLEX pricing has slowed from post-pandemic highs due to increased supply at lower price points, necessitating a volume-based growth strategy.
• CRE Marketplace: A significant opportunity exists in the commercial real estate sector with ~$1 trillion of loans maturing; a shift in asset supply from banks to non-bank lenders is expected to drive deal flow.
• Sector Expansion: Core business is expanding beyond pharma/biotech into broader industrial sectors (trucking, medical devices), broadening the pipeline for 2027.

Macro / Industry Outlook:

• Economic Environment: Management acknowledges a "lag" in the monetization of distressed assets compared to their initial timeline but views the current market as "solid and growing."
• Refinancing Strain: Highlights that many companies are struggling to refinance, creating a larger pool of distressed assets for monetization.
• Lending Trends: Alternative lending capital raises have not slowed, providing a steady pipeline of assets for NLEX (NPLs converting to charge-offs over 6–12 month cycles).
• FX/Tariffs: No specific commentary on currency, tariffs, or interest rates provided.

Strategic Initiatives:

• Integration: Full integration of three asset-light sectors (NLEX, Boston Note, Dedex) is targeted for completion by 2027.
• Sales Force Expansion: Dedex plans to expand its sales team to broaden coverage and capture deal flow from non-bank asset sellers.
• M&A Stance: No immediate urgency for additional M&A; focus is on organic growth and internal synergy realization following the Dedex and Boston Note acquisitions.
• Capital Allocation: Priority is on building cash reserves and financial flexibility (e.g., new $10M credit facility extending to Jan 2028) rather than immediate deployment; buyback programs and M&A are kept as options for high-conviction opportunities.
• Asset-Light Pivot: Complete shift in focus to asset-light sectors following the wind-down of the problematic HGC business.

Risks and Headwinds to Outlook:

• Dedex Monetization Speed: The timeline for monetizing commercial loans may be slower than anticipated if market refinancing conditions do not improve quickly.
• HGC Wind-Down Costs: Risk of extended operating/administrative costs if the wind-down is not completed rapidly in 2026.
• HGC Recovery Uncertainty: No guarantee on the recovery value of HGC assets; timing of any potential recovery is uncertain until 2027.
• Integration Challenges: Mixed performance of recent acquisitions (Dedex underperforming, Boston Note exceeding) highlights execution risks in integration.
• Market Volatility: Reliance on a "trailing benefactor" model implies the business is reactive to prior economic downturns; a change in the rate of Chapter 7 conversions could impact 2027 volume.

Management Tone on the Future:

• Confidence Level: High confidence ("poised to capture full potential," "very confident," "feeling pretty darn good") regarding the strategic pivot and core business momentum.
• Hedges: Explicitly notes "things to fix" and avoids "overconfidence," acknowledging that the HGC wind-down is not yet complete and Dedex is below expectations.
• Narrative: Framed as a "long race" (100-mile metaphor) where current quarters are rest stops; emphasis on a "bright finish" to the year and strong positioning for 2027 and beyond.

Miscellaneous:

• Financial Flexibility: Strengthened balance sheet with a new $10 million revolving line of credit from C3 Bank running through January 2028.
• Cash Position: Net available cash balance of $6.4 million as of September 30, 2026.
• Joint Venture: HGP invested $2 million in a Colorado joint venture acquiring two pharmaceutical sites; equipment monetization is immediate, real estate monetization is long-term (2027–2028).